Loading patent…
AssigneeMount Sinai School of Medicine of the City University of New York
InventorsAdolfo Garcia-Sastre, Peter Palese
Estimating the term…
This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using a DNA-directed RNA polymerase such as bacteriophage T7, T3 or the SP6 polymerase.
A recombinant RNA molecule comprising a binding site specific for an RNA-directed RNA polymerase of a Newcastle disease virus, operatively linked to a viral RNA containing a heterologous RNA sequence.
A recombinant RNA molecule comprising a binding site for an RNA-directed RNA polymerase of a Newcastle disease virus operatively linked to a Newcastle disease viral gene containing a mutation, which mutation results in an attenuating phenotype.
A chimeric virus comprising a negative strand RNA virus containing a viral RNA containing a heterologous RNA sequence comprising the reverse complement of a coding sequence derived from the genome of a Newcastle disease virus, operatively linked to a polymerase binding site of the negative strand RNA virus.
A method for producing a chimeric negative-strand RNA virus, comprising transfecting a host cell with nucleotide sequences encoding recombinant NDV and recovering the chimeric virus from the culture.
Dependencies are inferred from the claim text.